NCT07112378RecruitingPhase 3
A Randomized Study Evaluating 2 Dose Regimens of Dupilumab in Children ≥6 Months of Age Weighing ≥5 to <15 kg With Active Eosinophilic Esophagitis
Regeneron Pharmaceuticals14 sites in 1 country20 target enrollmentStarted: November 10, 2025Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Enrollment
- 20
- Locations
- 14
- Primary Endpoint
- Incidence of treatment-emergent Serious Adverse Events (SAEs)
Study Overview
Brief Summary
This study is researching an experimental drug called dupilumab (called "study drug"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding and nourishment.
The aim of the study is to see how safe, tolerable, and effective the study drug is when given for 24 weeks to children with active EoE.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Care Provider)
Eligibility Criteria
- Ages
- 6 Months to 6 Years (Child)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Pediatric patients aged ≥6 months and weighing ≥5 kg and <15 kg at screening with active EoE
- •History of symptom(s) determined by the investigator to be the result of EoE in the month prior to screening, as defined in the protocol
- •Baseline endoscopic biopsies, performed during the screening period, with a demonstration on central reading of intraepithelial eosinophilic infiltration in at least 2 of the 3 biopsied esophageal regions, as defined in the protocol
Exclusion Criteria
- •Prior participation in a dupilumab clinical trial or past or current treatment with dupilumab
- •Initiation or change of a food-elimination diet regimen or re-introduction of a previously eliminated food group in the 6 weeks prior to screening. Patients on a food-elimination diet must remain on the same diet throughout the study
- •Other causes of esophageal eosinophilia or the following conditions: eosinophilic gastroenteritis, hypereosinophilic syndrome, and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
- •Active Helicobacter pylori infection
- •History of Crohn's disease, ulcerative colitis, celiac disease, or prior esophageal surgery
- •Any esophageal stricture unable to be passed with a standard, diagnostic, upper endoscope or any critical esophageal stricture that requires dilation at screening
- •History of bleeding disorders or esophageal varices that, in the opinion of the investigator, would put the patient at undue risk for significant complications from an endoscopic procedure
- •Treatment with swallowed topical corticosteroids within 8 weeks prior to baseline standard of care endoscopy
- •NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply
Arms & Interventions
Dosing Regimen 2
Experimental
Intervention: dupilumab (Drug)
Dosing Regimen 1
Experimental
Intervention: dupilumab (Drug)
Outcomes
Primary Outcomes
Incidence of treatment-emergent Serious Adverse Events (SAEs)
Time Frame: Up to 24 Weeks
Secondary Outcomes
- Titer of ADA to dupilumab(Up to Week 36)
- Proportion of patients achieving peak esophageal intraepithelial eosinophil count of <15 eos/hpf (400×)(At Week 24)
- Incidence of Anti-Drug Antibody (ADA) to dupilumab(Up to Week 36)
- Incidence of Neutralizing Antibody (NAb) to dupilumab(Up to Week 36)
- Incidence of treatment-emergent Adverse Event of Special Interest (AESIs)(Up to 24 Weeks)
- Incidence of TEAEs(Up to 24 Weeks)
- Incidence of Treatment-Emergent Adverse Events (TEAEs) leading to permanent discontinuation of study treatment(Up to 24 Weeks)
- Proportion of patients achieving peak esophageal intraepithelial eosinophil count of ≤6 eosinophils per high power field (eos/hpf) (400×)(At Week 24)
- Percent change in peak esophageal intraepithelial eosinophil count (eos/hpf)(Baseline to Week 24)
- Change in body weight for age percentile(Baseline up to Week 24)
- Concentrations of functional dupilumab in serum(Baseline up to Week 24)
Investigators
Study Sites (14)
Loading locations...
Similar Trials
Active, not recruiting
Phase 2
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May HaveEosinophilic Gastritis (EoG)Eosinophilic Duodenitis (EoD)Eosinophilic Gastrointestinal Disease (EGID)Eosinophilic GastroenteritisNCT05831176Regeneron Pharmaceuticals22
Completed
Phase 2
Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult WomenNocturiaNCT01684800Ferring Pharmaceuticals178
Completed
Phase 2
Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult MenNocturiaNCT01694498Ferring Pharmaceuticals183
Completed
Phase 3
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)Dermatitis, AtopicNCT03345914Regeneron Pharmaceuticals367
Completed
Phase 3
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT02597049Eli Lilly and Company424